21 Mar '23
CAPE CANAVERAL, Fla., March 21, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced today that it has joined TransCelerate BioPharma, Inc. (TransCelerate) as the first emerging biotechnology
02 Mar '23
Vaxxinity to present new preclinical data on anti-tau Alzheimer’s vaccine candidate VXX-301 at AD/PD International Conference CAPE CANAVERAL, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic
05 Jan '23
DALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the